AEON Biopharma, Inc. Total Liabilities
AEON Biopharma, Inc. total liabilities. Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has total liabilities worth $28.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AEON Biopharma, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of AEON Biopharma, Inc. (2019–2024)
Total liabilities of AEON Biopharma, Inc. from 2019 to 2024. This chart illustrates how AEON Biopharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of AEON Biopharma, Inc. to see how much of total assets are deployed in long-term investments.
AEON Biopharma, Inc. Competitors by Total Liabilities
The table below lists competitors of AEON Biopharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Substrate AI S.A.
MC:SAI
|
Spain | €23.32 Million |
|
The European Smaller Companies Trust PLC
LSE:ESCT
|
UK | GBX84.81 Million |
|
MILA RESOUR. PLC LS-01
F:HN0
|
Germany | €116.74K |
|
VerifyMe Inc
NASDAQ:VRME
|
USA | $2.02 Million |
|
Real Heart
ST:HEART
|
Sweden | Skr13.59 Million |
|
Jet Freight Logistics Limited
NSE:JETFREIGHT
|
India | Rs1.05 Billion |
|
Orcay Ortakoy Cay Sanayi & Ticaret AS
IS:ORCAY
|
Turkey | TL419.20 Million |
|
Organoclick AB
ST:ORGC
|
Sweden | Skr121.59 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down AEON Biopharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AEON asset base.
Liquidity & Leverage Metrics
AEON Biopharma, Inc. Total Liabilities Ratios Explained
AEON Biopharma, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AEON Biopharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual total liabilities of AEON Biopharma, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $31.71 Million | -80.17% |
| 2023-12-31 | $159.89 Million | -43.14% |
| 2022-12-31 | $281.19 Million | +22.12% |
| 2021-12-31 | $230.26 Million | +2.59% |
| 2020-12-31 | $224.45 Million | +24.54% |
| 2019-12-31 | $180.22 Million | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more